Analysis of bone marrow samples of prostate cancer patients reveals a lack of Th1 cells in the tumor; high levels of TGF-β in prostate cancer bone metastases constrain the Th1 lineage, which confers resistance to ICI therapy [137]. The gene discussed is TGFB1; the disease is prostate carcinoma.